PTO/SB/08a (08-03)

PTO/SB/UBa (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a yaild OMB control number.

Complete if Known ubstitute for form 1449A/PTO 10/764,330 Application Number INFORMATION DISCLOSURE 01/23/2004 Filing Date Michael Cooke STATEMENT BY APPLICANT First Named Inventor 1645 Art Unit (Use as many sheets as necessary) Examiner Name P1097US10 Attorney Docket Number 2 Sheet of

EUT & TEAD OF

			U.S. PATENT	OCUMENTS		
Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant	
Initials *	Cite No.'	Number - Kind Code ² (if known)	MM-DD-YYYY		Figures Appear	
AJ	AA	US-5,583,033	12/10/1996	Terstappen, Leon W. M. M.		
AJ	AB	US- 5,677,139	10/14/2005	Johnason, R. Paul		
		US-		<u> </u>	<u></u>	
		US-				
		US-				
		U\$-	L			
	1	US-	L			
	1	US-				
	1	US-				
		US-				
	1	US-				
	1	US-				
		US-				
		US-				
,		US-			<u> </u>	
		US-	<u> </u>		-	
	1	US-	<u> </u>		 	
	1	US-			<u> </u>	
	1	US-				
	1	US-	·		<u> </u>	

		FOREIGN PA	TENT DOCU	MENTS		
	Cite No.'	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [©]
Examiner Initials*		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	 					!
	<u> </u>		 			1
	ļ					
	├					<u> </u>
	 					ļ
	1			<u> </u>	 	
	 					

Examiner Signature	Date Considered	

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ for Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if not document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if not document on a standard stan

PTO/SB/08b(08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known			
			•	Application Number	10/764,330		
INFO	RMATIC	ON DIS	CLOSURE	Filing Date	01/23/2004		
STAT	TEMEN1	BY A	PPLICANT	First Named Inventor	Michael Cooke		
		•		Art Unit	1645		
	(Use as many sheets as necessary)			Examiner Name			
Sheet	T ₂	of	2	Attorney Docket Number	P1097US10		

•		NON PATENT LITERATURE DOCUMENTS	·		
Examiner Initials *	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²		
AJ	AC	CHANG YT, et al. Related Articles, Links Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. Chembiochem. 2002 Sep 2;3(9):897-901.			
AJ	AD	IRVINE, Robin. Inositol phosphates: Does IP4 run a protection racket? Current Biology 2001. Vol 11, No. 5, p. 172-174.			
AJ	AE	IRVINE, Robin, et al. Back in The Water. The Return Of The Inositol Phosphates. Nature Reviews, Molecular Cell Biology. May 2001, Vol. 2, p. 327-338.			
AJ	AF	JUN, Kisun et al. Enhanced Hippocampal CA1 LTP but Normal Spatial Learning in Inositol 1,4,5-trisphosphate 3-kinase (A)-Deficient Mice. Learning & Memory, 1998, Vol 5, p. 317-330.			
AJ	AG	WOODRING, Pamela J. et al. Expression, Purification, and Regulation of Two Isoforms of the Inositol 1,4,5- Trisphosphate 3-Kinase. The Journal of Biological Chemistry, 1997, Vol. 272, No. 48, p. 30447-30454.	Ŀ		
AJ	АН	DEWASTE, Valerie, et al. Cloning and expression of a cDNA encoding human inositol 1,4,5-trisphosphate 3-kinase C. Biochem, 2000, p.343-351.			
	<u> </u>				
	 				

	Date	11/04/2006
miner / i man Tanada a /	Date	,,
I /AMW .IIIAAAS/	Considered	1
nature / Amy buedes/	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the complete this form and/or suggestions for reducing the complete